Financials in USD. Standardized financial statements.
A compact view of how Turning Point Therapeutics, Inc. turns revenue into operating income and net income.
| Metric | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|
| Revenue? | $30.83M | $25.00M | $0 | $0 | $0 |
| Revenue Growth? | +23.3% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $0 | $25.00M | $0 | $0 | $0 |
| Gross Profit? | $30.83M | $25 | $0 | $0 | $0 |
| Gross Margin? | +100.0% | +0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $268.83M | $186.84M | $77.72M | $25.64M | $16.73M |
| Operating Income? | -$236.55M | -$161.84M | -$77.72M | -$25.64M | -$16.73M |
| EBITDA? | -$232.58M | -$154.90M | -$70.55M | -$24.65M | -$16.53M |
| Income Before Tax | -$236.55M | -$157.29M | -$72.13M | -$24.78M | -$16.59M |
| Income Tax Expense | $0 | $0 | $0 | $1,000 | $1,000 |
| Net Income? | -$236.55M | -$157.29M | -$72.13M | -$24.79M | -$16.59M |
| EPS? | $-5.79 | $-3.85 | $-2.99 | $-1.66 | $-1.11 |
| Diluted EPS? | $-5.79 | $-3.85 | $-2.99 | $-1.66 | $-1.11 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality